OTCMKTS:MEOBF

Mesoblast Competitors

$1.34

0.00 (0.00 %)

(As of 05/14/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.34

▼

$1.34

50-Day Range

$1.34

▼

$1.73

52-Week Range

$1.34

▼

$9.99

VolumeN/A

Average Volume60,869 shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Mesoblast (OTCMKTS:MEOBF) Vs. DDXS, TNGN, ATTBF, ADTX, AGNPF, and LBTSF

Should you be buying MEOBF stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Mesoblast, including (DDXS) (DDXS), (TNGN) (TNGN), Abattis Bioceuticals (ATTBF), ADiTx Therapeutics (ADTX), Algernon Pharmaceuticals (AGNPF), and Almirall (LBTSF).

Mesoblast vs. (DDXS) Stock

Mesoblast (OTCMKTS:MEOBF) and (DDXS) (OTCMKTS:DDXS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for Mesoblast and (DDXS), as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	0	0	0	0	N/A
(DDXS)	0	0	0	0	N/A

Profitability

This table compares Mesoblast and (DDXS)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
(DDXS)	N/A	N/A	N/A

Earnings and Valuation

This table compares Mesoblast and (DDXS)'s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	N/A	N/A	N/A	N/A	N/A
(DDXS)	N/A	N/A	N/A	N/A	N/A

Mesoblast vs. (TNGN) Stock

Mesoblast (OTCMKTS:MEOBF) and (TNGN) (OTCMKTS:TNGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for Mesoblast and (TNGN), as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	0	0	0	0	N/A
(TNGN)	0	0	0	0	N/A

Profitability

This table compares Mesoblast and (TNGN)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
(TNGN)	N/A	N/A	N/A

Earnings and Valuation

This table compares Mesoblast and (TNGN)'s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	N/A	N/A	N/A	N/A	N/A
(TNGN)	N/A	N/A	N/A	N/A	N/A

Mesoblast vs. Abattis Bioceuticals Stock

Mesoblast (OTCMKTS:MEOBF) and Abattis Bioceuticals (OTCMKTS:ATTBF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for Mesoblast and Abattis Bioceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	0	0	0	0	N/A
Abattis Bioceuticals	0	0	0	0	N/A

Profitability

This table compares Mesoblast and Abattis Bioceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Abattis Bioceuticals	N/A	N/A	N/A

Earnings and Valuation

This table compares Mesoblast and Abattis Bioceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	N/A	N/A	N/A	N/A	N/A
Abattis Bioceuticals	N/A	N/A	N/A	N/A	N/A

Mesoblast vs. ADiTx Therapeutics Stock

Mesoblast (OTCMKTS:MEOBF) and ADiTx Therapeutics (NASDAQ:ADTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Profitability

This table compares Mesoblast and ADiTx Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
ADiTx Therapeutics	N/A	N/A	N/A

Earnings and Valuation

This table compares Mesoblast and ADiTx Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	N/A	N/A	N/A	N/A	N/A
ADiTx Therapeutics	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings for Mesoblast and ADiTx Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	0	0	0	0	N/A
ADiTx Therapeutics	0	0	1	0	3.00

Summary

ADiTx Therapeutics beats Mesoblast on 1 of the 1 factors compared between the two stocks.

Mesoblast vs. Algernon Pharmaceuticals Stock

Mesoblast (OTCMKTS:MEOBF) and Algernon Pharmaceuticals (OTCMKTS:AGNPF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Profitability

This table compares Mesoblast and Algernon Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Algernon Pharmaceuticals	N/A	N/A	N/A

Earnings & Valuation

This table compares Mesoblast and Algernon Pharmaceuticals' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	N/A	N/A	N/A	N/A	N/A
Algernon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Mesoblast and Algernon Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	0	0	0	0	N/A
Algernon Pharmaceuticals	0	0	0	0	N/A

Mesoblast vs. Almirall Stock

Mesoblast (OTCMKTS:MEOBF) and Almirall (OTCMKTS:LBTSF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Profitability

This table compares Mesoblast and Almirall's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Almirall	N/A	N/A	N/A

Earnings & Valuation

This table compares Mesoblast and Almirall's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	N/A	N/A	N/A	N/A	N/A
Almirall	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Mesoblast and Almirall, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	0	0	0	0	N/A
Almirall	0	1	1	0	2.50

Summary

Almirall beats Mesoblast on 1 of the 1 factors compared between the two stocks.